Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study

• Published in: Hepatology international Vol. 16; no. 2; pp. 282 - 293
• Main Authors: Ogawa, Eiichi, Nakamuta, Makoto, Koyanagi, Toshimasa, Ooho, Aritsune, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Satoh, Takeaki, Takahashi, Kazuhiro, Azuma, Koichi, Yamashita, Nobuyuki, Yamashita, Naoki, Sugimoto, Rie, Amagase, Hiromasa, Kuniyoshi, Masami, Ichiki, Yasunori, Morita, Chie, Kato, Masaki, Shimoda, Shinji, Nomura, Hideyuki, Hayashi, Jun
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.04.2022; Springer Nature B.V
• Subjects: Antigens; Antiretroviral drugs; Antiviral drugs; Cohort analysis; Colorectal Surgery; Data analysis; Deoxyribonucleic acid; DNA; Epidermal growth factor receptors; Glomerular filtration rate; Hepatitis; Hepatitis B; Hepatology; Interferon; Kidney diseases; Medicine; Medicine & Public Health; Original Article; Patients; Safety; Surgery; Tenofovir; Viruses; Hepatitis B virus; Sequential therapy; Tenofovir alafenamide; Tenofovir disoproxil fumarate; Entecavir

Background and aims Outcome data of sequential hepatitis B virus treatment with tenofovir alafenamide (TAF) are limited. We aimed to assess the effectiveness and renal safety of TAF in chronic hepatitis B (CHB) patients who were previously treated with entecavir (ETV), tenofovir disoproxil fumarate...